Article The GERAS Study - EU

GERAS is an 18-month, multicentre, prospective, non-interventional cohort study conducted in France, Germany, and the UK, designed to evaluate the costs and resource use associated with AD dementia for community-dwelling patients and their caregivers. Participants were enrolled between October 2010 and September 2011. Inclusion criteria were community-dwelling patients, aged at least 55 years, presenting within the normal course of clinical care, diagnosed with probable AD dementia according to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association criteria, with a Mini-Mental State Examination (MMSE) score of ≤26 points, and with an informal caregiver who was willing to participate in the study and undertake responsibility for the patient for at least 6 months of the year. Information was collected for patients and caregivers at the baseline visit and at 6, 12, and 18 months during routine care visits. Data collected included sociodemographic, comorbidities, medications, and health-related quality of life. Additional patient assessments included cognitive function (assessed using the MMSE and the cognitive subscale of the Alzheimer’s Disease Assessment Scale [ADAScog]), functional ability (assessed using the Alzheimer’s Disease Co-operative Study Activities of Daily Living Inventory [ADCS-ADL]), and behavioural and psychological symptoms (assessed using the Neuropsychiatric Inventory [NPI]). Caregivers also completed the Zarit Burden Interview (ZBI), which provides a measure of caregiver burden. Overall, 1,497 patients with AD dementia were enrolled into the study across the three MMSE severity domains Mild (MMSE 21-26; n=567), Moderate (MMSE 15-20; n=472) and Moderate/Severe (MMSE < 15; n=458), mean age 77.6 years; 55% female; with a mean time from diagnosis of 2.2 years.

Manuscripts citing this dataset

  • The Humanistic and Economic Burden of Alzheimer's Disease. 2022. DOI:
  • Resource utilization, costs and clinical outcomes in non-institutionalized patients with Alzheimer’s disease: 18-month UK results from the GERAS observational study. 2016. DOI:
  • The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries--study design and baseline findings. 2013. DOI: 3233/JAD-122392

Request Access

Data access can be requested via AD Workbench FAIR portal here. Access requests are automatically approved and the dataset will be delivered to your workspace Inbox upon user-initiated transfer. 

Data Use Agreement

More information on data access and use policies established by the trial sponsor can be found here.

Publishing results using this dataset?

The sponsor of this trial, Eli Lilly & Company, states their publication policy here.


Post a question or thought about this dataset here.